Abstract: The study aims to establish a method for simultaneous determination of repaglinide and pravastatin sodium in rat plasma by LC-MS/MS and to study its pharmacokinetic interactions. Eighteen male SD rats were divided into repaglinide group, pravastatin sodium group and co-administration group. Blood samples were collected at different times after oral administration. Repaglinide and pravastatin sodium in rat plasma were separated by Agilent HC-C₁₈ with the mobile phase consisting of methanol-0.1% formic acid (80:20). Detection and quantification were performed by using ESI-MS. The detector was operated in selected Reaction-monitoring mode at m/z 453.3→ 230.1 for repaglinide, m/z 447.2→ 327.4 for pravastatin sodium and m/z 285.1→ 192.9 for diazepam as the internal standard. The calibration curve obtained was linear (R² > 0.99) over the concentration range of 9.77-10 000 ng·mL^-1 for repaglinide and 4.88-625 ng·mL^-1 for pravastatin sodium. Compared with the single administration group, C_max and AUC_{0-6 h} of repaglinide increased significantly (P < 0.05) and t_max of pravastatin sodium prolonged (P < 0.05) in co-administration group. The method is found to be simple, sensitive and accurate for determining the concentration of repaglinide and pravastatin sodium in rat plasma. There exists pharmacokinetic interactions in the co-administration of repaglinide and pravastatin sodium.